Immatics N.V. Reports Q2 2025 Financial Results

Immatics N.V. ( (IMTX) ) has released its Q2 earnings. Here is a breakdown of the information Immatics N.V. presented to its investors.

Immatics N.V. is a clinical-stage biopharmaceutical company specializing in cancer immunotherapies, particularly focusing on precision targeting of PRAME, a cancer-associated antigen. The company is recognized for its innovative approach in developing T cell receptor-based therapies and bispecifics aimed at treating various cancers.

In its second-quarter 2025 earnings report, Immatics highlighted significant progress in its clinical trials, particularly for its lead product, anzu-cel (IMA203), a PRAME cell therapy for advanced melanoma. The company also reported a decrease in revenue and an increase in research and development expenses, reflecting its ongoing investment in clinical advancements.

Key financial metrics revealed a net loss of $82.4 million for the quarter, driven by reduced revenue from collaboration agreements and increased R&D expenses. Despite the financial challenges, Immatics maintains a strong cash position of $560.5 million, ensuring financial stability through the second half of 2027. The company is actively progressing its Phase 3 SUPRAME trial for anzu-cel, with interim and final analyses expected in 2026.

Strategically, Immatics is expanding its PRAME franchise with multiple ongoing trials, including IMA203CD8 and IMA402, targeting various cancer types. The company is also exploring opportunities beyond PRAME with its IMA401 bispecific targeting MAGEA4/8, focusing on head and neck cancer.

Looking ahead, Immatics remains committed to advancing its clinical programs and aims to bring its innovative therapies to market, addressing unmet medical needs in cancer treatment. The company anticipates further data updates in late 2025 and continues to build its pipeline for future growth.